| Careers | Contact Us

2017 Press releases
E-mail Alerts Receive e-mail alerts | RSS Rss feeds
Keyword search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011
07/10/17BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy CollaborationPrinter Friendly Version
06/01/17BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid TumorsPrinter Friendly Version
05/25/17BioLineRx Reports First Quarter 2017 Financial ResultsPrinter Friendly Version
05/22/17BioLineRx Announces Regulatory Submission for Phase 1b Trial of BL-8040 in Combination with Atezolizumab in AMLPrinter Friendly Version
05/16/17BioLineRx to Report First Quarter 2017 Results on May 25, 2017Printer Friendly Version
05/03/17BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDAPrinter Friendly Version
04/05/17BioLineRx Closes $28.75 Million Underwritten Public Offering of its American Depositary SharesPrinter Friendly Version
03/31/17BioLineRx Prices $25 Million Underwritten Public OfferingPrinter Friendly Version
03/30/17BioLineRx Announces Underwritten Public Offering of its American Depositary SharesPrinter Friendly Version
03/27/17BioLineRx's AGI-134 to be Presented at AACR 2017Printer Friendly Version
03/23/17BioLineRx Reports Year End 2016 Financial ResultsPrinter Friendly Version
03/23/17BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology PipelinePrinter Friendly Version
03/20/17BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization TreatmentPrinter Friendly Version
03/16/17BioLineRx to Report Annual 2016 Results on March 23, 2017Printer Friendly Version
02/07/17BioLineRx to Present at 2017 BIO CEO & Investor Conference in New York on February 14Printer Friendly Version
01/17/17BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic CancerPrinter Friendly Version
01/04/17BioLineRx to Present at Biotech Showcase 2017 Conference in San FranciscoPrinter Friendly Version

Interview with Philip Serlin, CEO
December 2016